Bolt Biotherapeutics (Bolt Biotherapeutics) Cash And Cash Equivalents : $10.81 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics Cash And Cash Equivalents?

Bolt Biotherapeutics's quarterly cash and cash equivalents declined from Jun. 2023 ($13.45 Mil) to Sep. 2023 ($9.16 Mil) but then increased from Sep. 2023 ($9.16 Mil) to Dec. 2023 ($10.81 Mil).

Bolt Biotherapeutics's annual cash and cash equivalents declined from Dec. 2021 ($27.38 Mil) to Dec. 2022 ($9.24 Mil) but then increased from Dec. 2022 ($9.24 Mil) to Dec. 2023 ($10.81 Mil).

Bolt Biotherapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Bolt Biotherapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics Cash And Cash Equivalents Chart

Bolt Biotherapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

34.83

5.54

27.38

9.24

10.81

Bolt Biotherapeutics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial														9.24	14.84	13.45	9.16	10.81

Bolt Biotherapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Bolt Biotherapeutics (NAS:BOLT) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Bolt Biotherapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Bolt Biotherapeutics (Bolt Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (NAS:BOLT) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

6LP:Germany

Address

900 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.boltbio.com

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.

Executives

William P. Quinn	officer: Chief Financial Officer	SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Edgar Engleman	director	575 HIGH STREET, STE 201, PALO ALTO CA 94301
Vivo Capital Fund Viii, L.p.	10 percent owner	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Laura Berner	director	C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Brian O'callaghan	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Frank D. Lee	director	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Kathleen Laporte	director
Miller Richard A Md	director	PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Mahendra Shah	director	2250 HOLCOMBE BLVD, HOUSTON TX 77030
Grant Yonehiro	officer: Chief Business Officer	C/O MAXYGEN, INC., 515 GALVESTON DRIVE, REDWOOD CITY CA 94063
Randall C Schatzman	director, officer: Chief Executive Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
David Dornan	officer: Chief Scientific Officer	C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Edith A. Perez	officer: Chief Medical Officer	C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTONE DRIVE, REDWOOD CITY CA 94063